Elanco Animal Health Faces Securities Fraud Class Action Over FDA Approval Delays
Key Insights
A securities fraud class action has been filed against Elanco Animal Health (search) due to potential violations of federal securities laws.
The lawsuit alleges that Elanco made misleading statements regarding the FDA approval timeline for Zenrelia (search) and Credelio Quattro (search).
Elanco's stock price dropped over 21% following the announcement of FDA approval delays and a boxed warning for Zenrelia (search).
Elanco Animal Health (search) Incorporated (NYSE:ELAN) is facing a securities fraud class action lawsuit filed on behalf of investors who suffered losses due to alleged misleading statements regarding the FDA approval of its key veterinary drugs, Zenrelia (search) and Credelio Quattro (search). The lawsuit, filed in the U.S. District Court of Maryland, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The core of the complaint revolves around Elanco's statements concerning the FDA's review of Zenrelia (search), a treatment for dermatitis (search) in dogs, and Credelio Quattro (search), a broad-spectrum oral parasiticide. The company had initially stated that the FDA possessed all necessary data for approval, with expectations for approval by the end of June 2024. However, on June 27, 2024, Elanco announced that the FDA would likely not approve either drug within the expected timeframe, and that Zenrelia would include a boxed warning on its label, indicating significant safety concerns.
Market Reaction and Investor Losses
The announcement of the FDA delays and the boxed warning for Zenrelia (search) triggered a significant drop in Elanco's stock price. On June 27, 2024, the stock price plummeted over 21%, falling from $17.97 per share to $14.27 per share. This decline resulted in substantial losses for investors, prompting the class action lawsuit.
Allegations of Misleading Statements
The lawsuit alleges that Elanco and certain of its executives made materially false and/or misleading statements to investors regarding the FDA approval prospects of Zenrelia (search) and Credelio Quattro (search). Specifically, the complaint questions the accuracy and completeness of Elanco's earlier statements, which suggested a smooth and timely approval process. The lawsuit aims to recover losses incurred by investors who relied on these statements.
Legal Options for Investors
Investors who purchased Elanco Animal Health (search) Incorporated (NYSE: ELAN) stock and suffered losses have the option to take legal action. Bleichmar Fonti & Auld LLP, the law firm representing the plaintiffs, encourages affected investors to submit their information to the firm to explore their legal options. The deadline for investors to seek appointment as lead plaintiff in the class action is December 6, 2024.
About Zenrelia and Credelio Quattro
Zenrelia (search) is designed to treat dermatitis (search) in dogs, a common condition characterized by skin inflammation and irritation. Credelio Quattro (search) is a broad-spectrum oral parasiticide intended to protect dogs from fleas, ticks, and internal parasites. Both treatments represent significant potential revenue streams for Elanco, making their FDA approval crucial for the company's financial performance.